BackInsmed Overview
Insmed Inc

Insmed Target Price

Analysts' average 12-month price target for Insmed is $190.

Get informed when a big investor buys or sells

+ Follow

Share Price

$114.14

Average Target Price

$192.1468.3% upside

14 analysts in the last 4 months

High: $235 | Low: $161

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-24Goldman Sachs$18864.7% upsideOpen
2026-09-15Roth CapitalAdam Walsh$19873.5% upsideOpen
2026-08-10Truist Financial$19570.8% upsideOpen
2026-08-07Morgan Stanley$21891% upsideOpen
2026-08-07Evercore ISI$17048.9% upsideOpen
2026-08-07Guggenheim$20579.6% upsideOpen
2026-08-07UBS$17250.7% upsideOpen
2026-08-07Wells Fargo$16948.1% upsideOpen
2026-08-06Jefferies$17553.3% upsideOpen
2026-07-28Cantor FitzgeraldOlivia Brayer$235105.9% upsideOpen
2026-07-20BMO CapitalConor MacKay$19268.2% upsideOpen
2026-07-20H.C. WainwrightAndrew Fein$22092.7% upsideOpen
2026-07-15Wells Fargo$16141.1% upsideOpen
2026-06-16Mizuho SecuritiesGraig Suvannavejh$19268.2% upsideOpen
2026-05-13Truist Financial$18562.1% upsideOpen
2026-05-08Wells Fargo$16040.2% upsideOpen
2026-05-08GuggenheimVamil Divan$22698% upsideOpen
2026-04-16Guggenheim$230101.5% upsideOpen
2026-04-14RBC Capital$21689.2% upsideOpen
2026-04-10Raymond James$20075.2% upsideOpen
2026-04-08Mizuho Securities$20277% upsideOpen
2026-03-26H.C. Wainwright$245114.6% upsideOpen
2026-02-24Mizuho Securities$20478.7% upsideOpen
2026-02-20Morgan Stanley$16645.4% upsideOpen
2026-02-20Wells FargoTiago Fauth$20882.2% upsideOpen
2026-02-19Stifel Nicolaus$20579.6% upsideOpen
2026-02-19Mizuho SecuritiesGraig Suvannavejh$21184.9% upsideOpen
2026-01-27BarclaysEliana Merle$231102.4% upsideOpen
2026-01-22Roth Capital$21285.7% upsideOpen
2026-01-21RBC CapitalLeonid Timashev$20075.2% upsideOpen
2026-01-12Truist FinancialDanielle Brill$20579.6% upsideOpen
2026-01-08Morgan StanleyMaxwell Skor$15737.6% upsideOpen
2026-01-06UBS$21588.4% upsideOpen
2025-12-19Truist FinancialDanielle Brill$20277% upsideOpen
2025-12-18H.C. Wainwright$230101.5% upsideOpen
2025-12-18Cowen & Co.$241111.1% upsideOpen
2025-12-18Mizuho SecuritiesGraig Suvannavejh$21285.7% upsideOpen
2025-12-18Guggenheim$22193.6% upsideOpen
2025-12-18Wedbush$20377.9% upsideOpen
2025-12-18RBC CapitalLeonid Timashev$19570.8% upsideOpen
2025-12-18Wells Fargo$19570.8% upsideOpen
2025-12-18Wolfe ResearchAndy Chen$16746.3% upsideOpen
2025-12-16Wells FargoTiago Fauth$234105% upsideOpen
2025-12-16Cantor FitzgeraldOlivia Brayer$230101.5% upsideOpen
2025-12-10Jefferies$269135.7% upsideOpen
2025-12-04Redburn Partners$263130.4% upsideOpen
2025-12-01Mizuho SecuritiesGraig Suvannavejh$256124.3% upsideOpen
2025-10-31Goldman Sachs$22597.1% upsideOpen
2025-10-31RBC CapitalLeonid Timashev$21588.4% upsideOpen
2025-10-31UBSTrung Huynh$22395.4% upsideOpen

Insmed (INSM) FAQ

The latest target price for INSM is $190. Investors often review this figure alongside Insmed's historical trend and sector peers before judging valuation or financial health.

Insmed trades near $114.14 while the consensus target sits at $190 (68.3% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting INSM's target price ($190), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Insmed's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.